Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative cancer therapies, particularly focusing on cell cycle regulation and apoptosis. With a strong emphasis on research and development, Cyclacel is dedicated to advancing its proprietary drug candidates, including the unique oral treatment, fadraciclib, which targets specific cancer pathways. Operating primarily in the oncology space, Cyclacel has established itself as a leader in the development of novel therapeutics that address unmet medical needs. The company’s commitment to scientific excellence has garnered recognition within the industry, positioning it favourably among peers. With a robust pipeline and strategic partnerships, Cyclacel Pharmaceuticals continues to push the boundaries of cancer treatment, striving to improve patient outcomes globally.
DitchCarbon Score
How does Cyclacel Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cyclacel Pharmaceuticals, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cyclacel Pharmaceuticals, Inc.'s reported carbon emissions
Cyclacel Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Cyclacel Pharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for Cyclacel to consider developing and communicating its climate strategies in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cyclacel Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
